Introduction
To provide. therapy by liver grafting has proved to be difficult for a variety of reasons; chief among these are shortage of suitable donors at the critical time when the operation is indicated in the recipient. When conventional treatment has failed to alter the inexorable course of fatal liver disease there are no satisfactory means available to restore the patient to a state of health that will enable him to withstand a major operation without serious hazard. Nevertheless, the alternative of early certain death is a greater risk, and faced with the choice, most patients are anxious to take the chance of liver transplantation. Starzl (1969) reported a one-year survival rate of 22% in his first 25 cases and if the patients operated on before 1967 are excluded the one-year figure rises to 33%.
Certain features of our series of liver grafts have already been reported (Calne and Williams, 1968; Calne et al., 1968; Williams et al., 1969; Calne, 1969; Williams, 1970) . Of 20 patients receiving orthotopic liver grafts, three failed to survive the operation and four died in the first postoperative week from a variety of causes. Four others died in hospital with survival periods of up to eight weeks. Three who were operated on recently are alive. Six were discharged home well and with excellent liver function-two dying from infection three months after operation, one at 41 months, and one at 11 months. The remaining two patients are alive-one in the eighth month, the other in the 18th after receiving an orthotopic liver graft. In this paper we describe the course of the last patient and that of the man who survived 11 months. A liver biopsy in October 1969 showed normal histological appearances, without significant portal tract infiltration. In April 1970 she was readmitted because of a rise in serum bilirubin to 2.6 mg./100 ml. and of serum aspartate aminotransferase to 114 i.u./100 ml. She had no symptoms and the episode settled over 10 days, the provisional diagnosis being mild cholangitis. At the time of writing she is in the 18th month after transplantation, continues to be well and to work part-time (see Fig.) . Her azathioprine dose is 100 mg. daily and the prednisolone has been reduced to 10 mg. day. Her serum bilirubin is 0-6 mg./100 ml., aspartate aminotransferase 63 i.u./100 ml., and alkaline phospha- (Williams, 1970 (Orr et al., 1969) 1969, 192 patients had died, six of them (3-1 %) from pulmonary embolism. Only 53 necropsies were performed, so it is possible that this figure is an underestimate. In seven patients
(1-8 ;(/',) the first presenting feature of myelomatosis was thromboembolism.
Discussion
There are only a few reports of thromboembolism complicating myelomatosis in the literature. In a clinicopathological study of myelomatosis Talerman (1969) found that massive pulmonary embolism was the cause of death in 3 out of 32 necropsies; he had not found this cause of death previously reported. Sanchez-Avalos et al. (1969) , searching for this complication in a clinical survey, recorded episodes of pulmonary embolism in 3 out of 34 patients. Two other cases were mentioned by Lieberman et al. (1961) , in one of which venous thrombosis had been present for nearly three years before the diagnosis of myelomatosis was established.
The mechanism of thrombosis in myelomatosis remains uncertain. Sanchez-Avalos et al. (1969) reported that certain laboratory findings were associated with thrombotic phenomena in myelomatosis-namely a shortening of the coagulation time in silicone tubes and an increase in the plasma fibrinogen concentration, suggesting the presence of a hypercoagulable state. An appreciable increase in the plasma concentration of fibrinogen (847 mg./100 ml.) and factor VIII (520 %/, of standard normal) was found in one of our three patients (Case 3) in whom coagulation studies were made. High fibrinogen levels have been reported in myelomatosis, especially with IgG paraprotein (Viala et al., 1963; Nilehn and Nilsson, 1966) . Plasma fibrinogen estimations however, may not be accurate in this condition owing to conjugation of the paraprotein with fibrinogen or occlusi,on in the fibrin clot (Bang, 1967; Regoeczi, 1968; Sanchez-Avalos et al., 1969) . In either case measurement of fibrinogen as thrombin-clottable protein would overestimate the true value. An increase in factor VIII has been found in myelomatosis as well as in other types of hyperglobulinaemia (Pitney and Elliott, 1960; Propp and Dylong, 1965; Nilehn and Nilsson, 1966) .
Increases in plasma fibrinogen and factor VIII have also been reported in patients with carcinoma (Mider et al., 1950; Amundsen et al., 1963) . Davis et al. (1969) , however, found that raised fibrinogen and factor VIII occurred in a number of non-malignant disorders and were not specific for malignant disease.
Malignant diseases, especially carcinoma, predispose to thrombosis (Lieberman et al., 1961; Miller et al., 1967; Wiernik and Serpick, 1969) . In some types of carcinoma, especially carcinoma of the pancreas, the incidence is very high. Different histological types of pancreatic carcinoma h.owever, are associated with pronounced differences in the incidence of multiple thrombi (Lafler and Hinerman, 1961) . It
